News

NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...
More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...
More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...
Cigna trades at a significant discount to the S&P 500, offering a higher yield and faster dividend growth, making it ...
The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...
The Cigna Group's fundamentals are solid, but the stock is fairly valued versus peers, not a bargain. Click here to find out ...
CI's commercial focus and clearer outlook set it apart as UNH faces guidance pulls, CEO change and rising medical costs.
A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.